Antipsychotic polypharmacy does not increase the risk for side effects

Schizophrenia Research

Volumn 98, Issue 1-3, 2008, Pages 323-324

  Ganesan, Soma ^a   Taylor, Ross ^a   Forbes, Ian ^b   Rabheru, Kiran ^a   Dumontet, Jane ^c   Procyshyn, Ric M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Vancouver General Hospital ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; NEUROTOXICITY; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; MALE; POLYPHARMACY; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 37049009748     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.09.002     Document Type: Letter

References (0)